Literature DB >> 34853989

Retrospective review of the clinical and laboratory data in silent lupus nephritis.

Figen Yargucu Zihni1, Gonca Karabulut2, Fahrettin Oksel2.   

Abstract

PURPOSE: To determine the ratio of renal disease necessitating immunosuppressive treatment in lupus patients who are clinically asymptomatic by means of renal disease. It was also examined whether silent lupus nephritis is associated with any of the non-renal clinical findings.
METHODS: All kidney biopsies performed in lupus patients between 1990 and 2009 at the Rheumatology Department of Ege University Faculty of Medicine were retrospectively screened. Among the 258 kidney biopsies screened, 54 had no clinical renal findings but had active disease together with anti-dsDNA positivity and/or hypocomplementemia. Patients were classified into two groups who require and do not require immunosuppressive therapy according to their final pathological results at biopsy. The frequency of serious renal involvement in the sample was calculated. Then subgroups were compared with each other in terms of the clinical and laboratory features using Statistical Package for Social Sciences version 13 software.
RESULTS: Thirteen of the 54 patients (24%) had severe renal involvement requiring immunosuppressant therapy. When the groups were compared to each other, it was found that serositis and hematologic involvement were significantly more frequent in patients who needed immunosuppressive treatment (42.9% versus 10.0%; p = 0.003 and 64.3% versus 37.5; p = 0.039).
CONCLUSION: Even in the absence of clinical renal manifestations, active patients at high risk of renal disease such as hypocomplementemia, anti-ds DNA positivity may have severe renal disease requiring immunosuppressive treatment. Thus, renal biopsy indications in lupus patients should better be revaluated.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Kidney biopsy; Lupus nephritis; Silent lupus nephritis; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2021        PMID: 34853989     DOI: 10.1007/s11255-021-03066-4

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.266


  3 in total

1.  Silent diffuse lupus nephritis: long-term follow-up.

Authors:  D J Leehey; A I Katz; A H Azaran; A J Aronson; B H Spargo
Journal:  Am J Kidney Dis       Date:  1982-07       Impact factor: 8.860

2.  Silent renal disease in systemic lupus erythematosus.

Authors:  J Font; A Torras; R Cervera; A Darnell; L Revert; M Ingelmo
Journal:  Clin Nephrol       Date:  1987-06       Impact factor: 0.975

3.  Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.

Authors:  Thomas Wais; Walter Fierz; Thomas Stoll; Peter M Villiger
Journal:  J Rheumatol       Date:  2003-10       Impact factor: 4.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.